Viva Biotech Holdings (HKG:1873)
Hong Kong · Delayed Price · Currency is HKD 1.280
-0.050 (-3.76%)
Sep 11, 2026, 4:08 PM HKT
Viva Biotech Holdings Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,904 | 1,729 | 1,987 | 2,156 | 2,380 | 2,104 | |
Revenue Growth | 3.67% | -12.95% | -7.84% | -9.41% | 13.10% | 201.89% |
Cost of Revenue | 1,246 | 1,074 | 1,299 | 1,417 | 1,564 | 1,453 |
Gross Profit | 657.86 | 655.56 | 687.4 | 738.43 | 815.68 | 650.98 |
Selling, General & Admin | 352.1 | 363.91 | 364.12 | 409.66 | 404.45 | 320.29 |
Research & Development | 117.19 | 100.46 | 87.99 | 127.97 | 135.84 | 92.38 |
Other Operating Expenses | - | - | - | - | 3.37 | - |
Operating Expenses | 469.03 | 462.31 | 457.73 | 545.75 | 549.7 | 414.08 |
Operating Income | 188.83 | 193.25 | 229.67 | 192.68 | 265.98 | 236.9 |
Interest Expense | -34.2 | -37.52 | -53.89 | -176.58 | -184.67 | -183.11 |
Interest & Investment Income | 16.53 | 16.92 | 20.54 | 27.38 | 21.61 | 26.58 |
Earnings From Equity Investments | -4.38 | -4.5 | -0.1 | - | - | - |
Currency Exchange Gain (Loss) | -24.78 | 5.44 | 16.18 | -51.01 | -146.39 | 31.41 |
Other Non Operating Income (Expenses) | 16.08 | 18.34 | 32.7 | 210.93 | -4.33 | 188.05 |
EBT Excluding Unusual Items | 158.09 | 191.94 | 245.1 | 203.39 | -47.81 | 299.83 |
Gain (Loss) on Sale of Investments | 125.59 | 146.55 | 91.12 | -11.68 | -364.18 | 55.16 |
Gain (Loss) on Sale of Assets | -4.16 | -4.67 | -1.91 | 0.28 | -1.9 | -5.2 |
Asset Writedown | -23.79 | -15.99 | -38.61 | -25.19 | -6.57 | -2.1 |
Other Unusual Items | 0.17 | 0.17 | - | -222.76 | -38.7 | - |
Pretax Income | 255.91 | 318 | 295.71 | -55.95 | -459.17 | 347.7 |
Income Tax Expense | 34.4 | 48.74 | 73.72 | 43.84 | 45.06 | 47.14 |
Earnings From Continuing Operations | 221.51 | 269.27 | 221.99 | -99.79 | -504.22 | 300.56 |
Minority Interest in Earnings | -43.48 | -49.51 | -54.69 | -16.32 | -24.26 | -13.01 |
Net Income | 178.03 | 219.76 | 167.29 | -116.11 | -528.48 | 287.55 |
Net Income to Common | 178.03 | 219.76 | 167.29 | -116.11 | -528.48 | 287.55 |
Net Income Growth | 3.33% | 31.36% | - | - | - | - |
Shares Outstanding (Basic) | 2,108 | 2,111 | 2,137 | 1,940 | 1,915 | 1,912 |
Shares Outstanding (Diluted) | 2,266 | 2,339 | 2,868 | 2,029 | 1,915 | 1,971 |
Shares Change | -25.76% | -18.44% | 41.39% | 5.91% | -2.81% | 25.41% |
EPS (Basic) | 0.08 | 0.10 | 0.08 | -0.06 | -0.28 | 0.15 |
EPS (Diluted) | 0.07 | 0.09 | 0.06 | -0.14 | -0.28 | 0.08 |
EPS Growth | 10.29% | 50.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 302.06 | 111.07 | 183.32 | 195.73 | 136.72 | -487.35 |
Free Cash Flow Per Share | 0.13 | 0.05 | 0.06 | 0.10 | 0.07 | -0.25 |
Gross Margin | 34.55% | 37.91% | 34.60% | 34.26% | 34.28% | 30.94% |
Operating Margin | 9.92% | 11.17% | 11.56% | 8.94% | 11.18% | 11.26% |
Profit Margin | 9.35% | 12.71% | 8.42% | -5.39% | -22.21% | 13.67% |
Free Cash Flow Margin | 15.86% | 6.42% | 9.23% | 9.08% | 5.75% | -23.16% |
EBITDA | 377.04 | 385.38 | 432.78 | 391.01 | 436.35 | 369.94 |
EBITDA Margin | 19.80% | 22.28% | 21.78% | 18.14% | 18.34% | 17.58% |
D&A For EBITDA | 188.2 | 192.13 | 203.11 | 198.33 | 170.37 | 133.04 |
EBIT | 188.83 | 193.25 | 229.67 | 192.68 | 265.98 | 236.9 |
EBIT Margin | 9.92% | 11.17% | 11.56% | 8.94% | 11.18% | 11.26% |
Effective Tax Rate | 13.44% | 15.32% | 24.93% | - | - | 13.56% |